Screening for Type 1 Diabetes

This content originally appeared on Beyond Type 1. Republished with permission.

If you have a relative with type 1 diabetes, you may be at higher risk of developing the disease, making it imperative that you get screened. There are now simple blood tests that can determine your risk of developing type 1 diabetes before symptoms occur. Not only are there significant benefits to early detection, but as undiagnosed type 1 can be fatal, screening saves lives. Benefits to getting screened for type 1 diabetes (T1D) include:

  • Detecting T1D early reduces the likelihood of Diabetic Ketoacidosis and Hospitalization at diagnosis.
  • Opportunities to participate in clinical trials to prevent or delay the onset of T1D for years after screening
  • Knowing your results gives you peace of mind and time to prepare

For more information on the benefits of screening check out this interview with JDRF Director of Research Frank Martin and read 5 Reasons to Get Screened for Type 1 Diabetes.

Learn More About Screening Options

T1Detect From JDRF

Mom

Image source: Beyond Type 1

T1Detect, JDRF’s screening education and awareness program, will arm you with the information you need before and after getting screened for type 1 diabetes autoantibodies. Until now, T1D symptoms and a diagnosis often come out of the blue. Today, families can use testing to detect T1D early so they can plan and prepare. With one blood test, anyone at any age can find out—before symptoms even occur—if they are at risk for developing T1D. The test is easy, simple and can help save lives. Everyone, regardless of relation to someone with confirmed T1D, is eligible.

TrialNet

TrialNet

Image source: Beyond Type 1

If you have a relative with T1D, you’re in a unique position to help us learn more about the disease and how to prevent it. Offered through the TrialNet Pathway to Prevention Study, risk screening uses a simple blood test that can detect your risk of T1D years before symptoms appear. If you are in the early stages of T1D, you may be eligible for a prevention study. Take the first step and get screened.

Read the Latest Screening News

T1Detect is a new screening initiative designed to make early detection of type 1 diabetes easier and more accessible to a broad population. More

New Evidence Shows Vital Importance of Screening For T1D in Children

Kid

Image source: Beyond Type 1

By screening for type 1 diabetes in children, Bavaria was able to decrease rates of diabetic ketoacidosis at diagnosis. More

Firsthand Screening Accounts

Knowledge is Power: Screening for T1D

Family

Image source: Beyond Type 1

After their first daughter was diagnosed with T1D, the Brzozowski family decided to have their youngest child screened, and discovered that she would eventually develop Type 1 diabetes. More

My Decision to Get Screened for T1D

Family

Image source: Beyond Type 1

Jorge Aguilar’s mom has had T1D for his entire life; he explains his decision to be screened for T1D antibodies and offers advice to others who are considering being screened. More

Source: diabetesdaily.com

Breaking Updates from TrialNet (ADA 2020)

TrialNet is a research effort that seeks to identify preventative and treatment strategies for type 1 diabetes. New data was just released at the American Diabetes Association (ADA) 80th Scientific Sessions. Here are the major highlights:

1. The optimal age for screening children at risk for type 1 diabetes

It is possible to screen at-risk individuals for the development of autoantibodies that are predictive of T1D development. This can reduce the likelihood of health complications due to a late diagnosis as well as allow patients to enroll in clinical trials aimed at preventing or delaying T1D onset. Researchers recently evaluated the sensitivity, specificity and predictive values based on the screening ages of children at risk for developing T1D. They concluded that it was best for two separate screenings to occur; one around the age of 2-3 years and another at around the age of 5-6 years. “Our data represent a starting point for these considerations that should be customized based on the population’s underlying disease characteristics and public health infrastructure,” they added.

2. Identifying those at risk

How do we identify those who are most at risk for developing T1D? Currently, beta cell function analysis, utilizing glucose tolerance tests and other, more invasive measures, are used. New research demonstrates that using a validated (in type 2 diabetes) mathematical tool may be able to help make this assessment for those at risk for type 1 diabetes from “fasting glucose and insulin measurements from a single time point.” This could afford a fast and relatively non-invasive way to predict risk in the future.

3. Antibody-positive individuals with very slow progression to type 1 diabetes

It is established that people can develop T1D at different rates, after the initial appearance of autoantibodies. New research aimed to characterize the features of “long-term non-progressors.” Interestingly, data revealed that those whose disease onset did not progress long after autoantibody detection, still had a decline in beta cell function, but nevertheless exhibited largely stable glucose profiles and c-peptide levels. Researchers speculate that glucose tolerance testing in those with autoantibodies may help identify those who are less likely to progress to T1D.

4. Pancreas volume and type 1 diabetes progression

New research demonstrates that not only is pancreas size at the onset of T1D and in those at risk smaller, pancreas size is also predictive of T1D risk. The study evaluated those with “stage 1” T1D (those who have two or more autoantibodies, but normal glucose tolerance) and found that their pancreas volume was significantly smaller than that of healthy controls (but significantly larger than those with “stage 3” T1D (showing autoimmunity and hyperglycemia, with symptoms). Although the sample size was relatively small, the data indicate that pancreas size (as measured by MRI) could be a predictive indicator of T1D development.

5. Oral insulin for those at risk of developing type 1 diabetes

Relatives of people with type 1 diabetes (T1D) who were identified as “high-risk” for also developing the condition participated in a prevention trial that used oral insulin (OI) in this population. While overall, the treatment did not appear to be effective in preventing T1D in initial analyses, a further analysis of patient subgroups revealed an interesting trend. Among those who were identified as being at the highest risk for developing T1D (high auto-antibody levels; hindered first-phase insulin response), data indicate that OI can “slow insulin decline”.

Read more about TrialNet and the work they’re doing here:

New Treatment Delays Type 1 Diabetes

Please share this article and stay tuned for more news from the ADA Scientific Sessions.

Source: diabetesdaily.com

Search

+